Immunotherapy, such as programmed cell death 1 (PD‐1)/programmed cell death ligand 1 (PD‐L1)/cytotoxic T‐lymphocyte antigen 4 (CTLA‐4) inhibitors, is another parallel approach for the treatment of melanoma. Here, CTLA4 is linked to melanoma.